IP Library Granted Patent US 8,983,579
Granted Patent B2
US 8,983,579 · App. 13/794,141 · Granted Mar 17, 2015

Syringe with visual use indicator

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,983,579
App. No.
13/794,141
Granted
Mar 17, 2015
Kind
B2
Abstract

Systems and methods are presented for the visual indication of whether a power injector has discharged fluid from a power injector syringe in a previous medical procedure. In this regard, the systems and methods generally provide for a power injector and a syringe for use with the power injector. The syringe includes a visual indicator that moves between a first state and a second state at approximately the same time that the power injector discharges fluid from the syringe such that an operator may view the change in state.

Claims (25)

1. A syringe, comprising:

a syringe body that defines an internal fluid discharge chamber and that comprises a movable member exposed to pressure within said internal fluid discharge chamber;

a syringe plunger movably disposed within said syringe body; and

a fluid source disposed outside of said fluid discharge chamber, wherein said movable member is aligned with said fluid source, wherein said movable member moves in response to pressurization within said internal fluid discharge chamber generated b movement of said syringe plunger relative to said syringe body, and wherein movement of said movable member releases a first fluid from said fluid source to provide a visual indication that fluid has been discharged from said syringe body.

2. The syringe of claim 1 , wherein said fluid source comprises an enclosure, wherein said first fluid is contained within said enclosure.

3. The syringe of claim 2 , wherein said enclosure is a deformable member.

4. The syringe of claim 2 , wherein said enclosure ruptures upon exposure to at least a certain pressure.

5. The syringe of claim 2 , wherein said enclosure comprises a blister pack.

6. The syringe of claim 1 , further comprising a flowpath fluidly interconnectable with said fluid source.

7. The syringe of claim 6 , wherein said fluid source and said flowpath are fluidly isolated when said syringe is in a first state, and wherein said fluid source communicates with said flowpath when said syringe is in a second state.

8. The syringe of claim 7 , wherein said first state is prior to an advancement of said syringe plunger to discharge fluid from said syringe body, and wherein said second state is a development of a differential pressure in response to an advancement of said syringe plunger to discharge fluid from said syringe body.

9. The syringe of claim 6 , wherein an exterior surface of said syringe body comprises a channel, and wherein said channel comprises said flowpath.

10. The syringe of claim 9 , wherein said channel extends at least about 10% of a length of said syringe body.

11. The syringe of claim 9 , further comprising a label disposed over said channel.

12. The syringe of claim 1 , wherein said movable member moves from a first position to a second position in response to a differential pressure that develops by advancement of said syringe plunger.

13. The syringe of claim 12 , wherein said first fluid is released from said fluid source in response to said movable member moving from said first position to said second position.

14. The syringe of claim 1 , wherein said movable member comprises a dimple.

15. The syringe of claim 14 , wherein said dimple inverts in response to movement of said syringe plunger.

16. The syringe of claim 14 , wherein said dimple is convex on an interior of said syringe and is concave on an exterior of said syringe prior to movement of said syringe plunger in a direction to discharge fluid from said syringe.

17. The syringe of claim 16 , wherein movement of said syringe plunger in a direction to discharge fluid from said syringe inverts said dimple so that said dimple is concave on said interior of said syringe and is convex on said exterior of said syringe.

18. The syringe of claim 14 , wherein inversion of said dimple in response to movement of said syringe plunger ruptures said fluid source.

19. The syringe of claim 1 , wherein said movable member comprises a deformable section of said syringe.

20. The syringe of claim 1 , wherein said syringe body comprises a barrel and a discharge port, and wherein said fluid source is located between said barrel and said discharge port.

21. The syringe of claim 1 , wherein said syringe comprises a frustumly-shaped surface, and wherein said fluid source coincides with said frustumly-shaped surface.

22. The syringe of claim 1 , wherein said first fluid of said fluid source comprises a colored liquid.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
RELEASE OF SECURITY INTEREST Recorded Nov 30, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 037172/0094 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2014
From: MALLINCKRODT LLC
To: LIEBEL-FLARSHEIM COMPANY LLC
Reel/Frame 034715/0531 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →